MedTrace Logo

Myocardial Perfusion and Fibrosis in Cancer Survivors

NCT03191461 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2024-10-30

No results posted yet for this study

Summary

This is a cross-sectional pilot study. The investigators seek to obtain early information pertaining to the relationship between measurements of myocardial perfusion reserve and myocardial fibrosis after receipt of Anthracycline-based chemotherapy (≥2 years prior).

Conditions

  • Myocardial Fibrosis
  • Myocardial Injury
  • Chemotherapeutic Toxicity

Interventions

DIAGNOSTIC_TEST

Adenosine stress test MRI

Participants will receive a contrasted adenosine stress CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Solutions, Malvern, PA) dedicated to cardiovascular imaging. Adenosine stress was selected due to attenuated endothelium dependent and -independent vasodilation after doxorubicin receipt in humans to allow the investigators to understand the potential effect of perivascular fibrosis on perfusion reserve. Standardized CMR protocols will be performed to measure LV volumes (to assess wall motion abnormalities and identify any potential myocardial dysfunction), Native T1, ECV, and myocardial perfusion reserve in the short-axis plane

Sponsors & Collaborators

  • Wake Forest University

    collaborator OTHER

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Jennifer H Jordan, PhD · Virginia Commonwealth University

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-13
Primary Completion
2024-04-11
Completion
2024-04-11
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03191461 on ClinicalTrials.gov